CN107095870B - 一种具有抗淋巴瘤作用的复方药物组合物及其用途 - Google Patents
一种具有抗淋巴瘤作用的复方药物组合物及其用途 Download PDFInfo
- Publication number
- CN107095870B CN107095870B CN201710443193.1A CN201710443193A CN107095870B CN 107095870 B CN107095870 B CN 107095870B CN 201710443193 A CN201710443193 A CN 201710443193A CN 107095870 B CN107095870 B CN 107095870B
- Authority
- CN
- China
- Prior art keywords
- effect
- medicament composition
- compound medicament
- piperlongumine
- lymphadenoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 230000000694 effects Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- VABYUUZNAVQNPG-UHFFFAOYSA-N Piperlongumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-UHFFFAOYSA-N 0.000 claims abstract description 39
- VABYUUZNAVQNPG-BQYQJAHWSA-N Piplartine Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-BQYQJAHWSA-N 0.000 claims abstract description 39
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 claims abstract description 38
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940079593 drug Drugs 0.000 claims description 25
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 12
- 239000000470 constituent Substances 0.000 abstract description 3
- 239000000890 drug combination Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 description 7
- 240000000691 Houttuynia cordata Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 235000013717 Houttuynia Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000020995 raw meat Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000207658 Piper sylvaticum Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- -1 acetaldehyde Compound Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- GGOVLAUMYLPYAZ-UHFFFAOYSA-N puberulumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2CCCCC2)=C1 GGOVLAUMYLPYAZ-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HPPWMWCITPGPKK-UHFFFAOYSA-M sodium;1-hydroxy-3-oxododecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCC(=O)CC(O)S([O-])(=O)=O HPPWMWCITPGPKK-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710443193.1A CN107095870B (zh) | 2017-06-13 | 2017-06-13 | 一种具有抗淋巴瘤作用的复方药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710443193.1A CN107095870B (zh) | 2017-06-13 | 2017-06-13 | 一种具有抗淋巴瘤作用的复方药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107095870A CN107095870A (zh) | 2017-08-29 |
CN107095870B true CN107095870B (zh) | 2019-05-21 |
Family
ID=59660267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710443193.1A Active CN107095870B (zh) | 2017-06-13 | 2017-06-13 | 一种具有抗淋巴瘤作用的复方药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107095870B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109602744A (zh) * | 2018-12-13 | 2019-04-12 | 中国人民解放军总医院 | 荜茇酰胺在制备抗菌消炎药物中的应用 |
CN109620836B (zh) * | 2018-12-24 | 2021-05-18 | 陕西科技大学 | 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002041828A2 (en) * | 2000-11-17 | 2002-05-30 | Dajun Yang | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon |
CN102125552A (zh) * | 2010-01-20 | 2011-07-20 | 李绍路 | 荜茇酰胺衍生物在制备治疗癌症的药物中的用途及其药物组合物 |
CN102146054A (zh) * | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
-
2017
- 2017-06-13 CN CN201710443193.1A patent/CN107095870B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002041828A2 (en) * | 2000-11-17 | 2002-05-30 | Dajun Yang | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon |
CN102125552A (zh) * | 2010-01-20 | 2011-07-20 | 李绍路 | 荜茇酰胺衍生物在制备治疗癌症的药物中的用途及其药物组合物 |
CN102146054A (zh) * | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN107095870A (zh) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ajibade et al. | Phytochemical screening and toxicity studies on the methanol extract of the seeds of Moringa oleifera | |
Thejass et al. | Immunomodulatory activity of Sulforaphane, a naturally occurring isothiocyanate from broccoli (Brassica oleracea) | |
CN101495108B (zh) | 用于抗性癌症治疗的包含冬凌草甲素的组合物 | |
WS Ho et al. | Combination of phytochemicals as adjuvants for cancer therapy | |
CN107095870B (zh) | 一种具有抗淋巴瘤作用的复方药物组合物及其用途 | |
TWI678211B (zh) | 管花肉蓯蓉萃取物及異類葉升麻苷於保護肌肉之用途 | |
CN103479963A (zh) | 一种治疗类风湿关节炎的中药胶囊及其制备方法 | |
CN104814972A (zh) | 一种含有人参皂苷的药物组合物 | |
CN107260734A (zh) | 一种具有抗肺癌作用的复方药物组合物及其用途 | |
CN112089710B (zh) | 4-羟基异亮氨酸在制备抗肿瘤药物中的应用 | |
CN108159061B (zh) | 虎杖苷紫杉醇组合物及在制备防治胃部恶性肿瘤药物的用途 | |
WO2016169487A1 (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素的组合物在制备抗炎药物中的应用 | |
CN101953839B (zh) | 一种具有抗急性髓性白血病作用的复方药物组合物 | |
KR101620153B1 (ko) | 갯방풍 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
JP2015515993A (ja) | ヒトシクロオキシゲナーゼ及びドキソルビシン又はドキソルビシン類を含有する医薬組成物、その調製方法及び多種薬物の製造における使用 | |
CN102091312A (zh) | 生姜与花椒组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN107260721A (zh) | 一种复方药物组合物及其用途 | |
CN103479649B (zh) | 一种药物组合物及其应用 | |
CN106511360A (zh) | 一种含有人参皂苷Rg3和水飞蓟素的组合物及药物 | |
CN101099769B (zh) | 连翘在制备抗肿瘤化疗增敏减毒药物中的应用 | |
CN105246472B (zh) | 含有鸟氨酸和/或门冬氨酸的组合物及其应用 | |
CN108721302A (zh) | 一种复方药物组合物及其用途 | |
CN107375314A (zh) | 一种丫蕊花甾体皂苷 yb16和甘草次酸复方药物组合物及其用途 | |
CN1302797C (zh) | 一种抗肿瘤血管栓塞剂及其制备方法 | |
Khanal et al. | Bioactive compounds and nanoparticles in Ganoderma lucidum: New perspectives on health benefits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170829 Assignee: Zhongke cell technology (Guangzhou) Co.,Ltd. Assignor: FOSHAN University Contract record no.: X2022980018374 Denomination of invention: A compound drug composition with anti lymphoma effect and its use Granted publication date: 20190521 License type: Common License Record date: 20221013 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170829 Assignee: GUANGZHOU RANSHAO MEDICAL TECHNOLOGY DEVELOPMENT CO.,LTD. Assignor: FOSHAN University Contract record no.: X2022980018321 Denomination of invention: A compound drug composition with anti lymphoma effect and its use Granted publication date: 20190521 License type: Common License Record date: 20221019 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170829 Assignee: GUANGZHOU JUENUO MEDICAL EQUIPMENT CO.,LTD. Assignor: FOSHAN University Contract record no.: X2023980037158 Denomination of invention: A compound drug composition with anti lymphoma effect and its use Granted publication date: 20190521 License type: Common License Record date: 20230630 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170829 Assignee: Chongqing Zhixin Yicheng Biotechnology Co.,Ltd. Assignor: FOSHAN University Contract record no.: X2023980049750 Denomination of invention: A compound drug combination with anti lymphoma effect and its use Granted publication date: 20190521 License type: Common License Record date: 20231204 |